The global aerosol delivery devices market is foreseen to expand at a CAGR of 4.9% and reach the valuation of USD 46.72bn in 2027 in comparison to USD 31.46bn in 2019.
Aerosol
drug devices can treat a host of diseases such as lung diseases, pneumonia,
diabetes, asthma, etc. which further drives the global aerosol delivery devices
market during the forecast years.
Researchmoz
elucidates the market in detail including market size, opportunities,
restraints, drivers, and segment domination.
Chronic obstructive pulmonary disease (COPD)
to Drive the Market
Chronic
obstructive pulmonary disease (COPD) is the most common death-causing disease
in the world and drug delivery via inhalation process is the common treatment
for COPD. The disease affects nearly 15% of the US population, thus, the
increasing prevalence of COPD is projected to drive the global aerosol delivery
devices market.
The
drug delivery system has had a transformational shift since its inception, from
just metered-dose inhalers to handheld inhalers such as dry powder and soft
mist inhalers. The growing patient population and growing need for targeted
therapies have encouraged a better understanding of the applications of aerosol
drug delivery.
Self-administration to Boost the Sales of
Aerosol Delivery Devices
The
pharmaceutical industry is highly focused on patient-centricity through
bringing in self-administration and giving ease and real-time experiences to
the patients, owing to the expansion of the global aerosol delivery devices
market.
According
to pharma experts, innovations in the field of drug delivery will make
manufacturers and pharma companies, researchers, and scientists to work
together and introduce digitization, leading to the expansion of the global
aerosol delivery devices market.
The
high cost of treatment and side effects of medication might hinder the growth
of the global aerosol delivery devices market to some extent.
However,
the rising geriatric population with severe respiratory diseases such as
asthma, COPD, etc. will drive the global aerosol delivery devices market.
Analysts Views
Non-respiratory
diseases such as diabetes, thyroid, Parkinson’s disease, and some genetic
disorders will also drive the global aerosol drug delivery market during the
forecast years.
The
dry powder inhalers segment will be the aerosol delivery device market over the
forecast period due to its efficacy and design.
The
common line of treatment is inhalation therapy in diseases such as asthma,
which would encourage growth opportunities in the global aerosol delivery
devices market in the coming years.
Asia
Pacific will hold a larger share in the global aerosol delivery devices market,
owing to the prevalence of diseases like asthma, COPD, Pneumonia, etc.
Competitive Landscape
Reasearchmoz
puts forth a comprehensive report about the competitive landscape of the
aerosol delivery devices market. The report includes all the aspects of the
market including the strategies that key companies are focusing on in order to
thrive in the global market and tap into untouched areas.
Some of the prominent
players in the global aerosol drug delivery market are-
- Koninklijke Philips N.V.
- 3M Company
- Aerogen, INC
- GlaxoSmithKline Plc (GSK)
- Merck & co., INC.
- Metall Zug Group (Clement Clarke International
Ltd)
- Merxin LTD
- Nemera
- Iconovo AB
- Gerresheimer AG
- Recipharm AB (Bespak)
- Johnson & Johnson (Actelion
Pharmaceuticals Ltd)
- Teva Pharmaceutical Industries Limited
- Vectura Group PLC
To
Know the Scope of Our Report Get A FREE Sample Now @ https://www.researchmoz.us/request-free-sample/?reportid=531
No comments:
Post a Comment